5 completed, 2 recruiting. 2 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Urgency Incontinence: new trials by email Literature Review of Urgency Incontinence trials Research Report on Urgency Incontinence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining Ileorectal Syndrome: a Prospective Observational Study survey study - Total Colectomy, Diarrhea | Recruiting | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital | 30 | 2025-12-19 | 2026-02-03 | |
| Implementation of the App Tät®II for Treatment of Urgency and Mixed Urinary Incontinence Tät®II - Urgency Incontinence, Mixed Incontinence, Urge and Stress | Recruiting | Umeå University | 60 | 2025-06-12 | 2025-06-26 | |
| The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence OnabotulinumtoxinA (Botox ®) Injections, Saline Injections - Mixed Urinary Incontinence, Stress Urinary Incontinence | Phase 4 | Completed | Northwestern University | 100 | 2016-02-01 | 2023-03-14 |
| A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice Betmiga® - Urgency Incontinence, Urinary Bladder Overactive | Completed | Astellas Pharma Europe Ltd. | 863 | 2014-11-25 | 2024-10-31 | |
| Controlling Urgency Through Relaxation Exercises Paced Respiration, Music Therapy - Overactive Bladder, Urgency Urinary Symptoms | Not applicable | Completed | University of California, San Francisco | 161 | 2014-09-01 | 2019-07-30 |
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin - Urinary Bladder Overactive, Overactive Bladder | Phase 3 | Completed | Astellas Pharma Europe B.V. | 1829 | 2014-03-17 | 2024-10-31 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate - Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases | Phase 3 | Completed | Astellas Pharma Europe B.V. | 3527 | 2013-11-05 | 2024-10-31 |
Urinary Bladder, Overactive (4) · Urinary Incontinence (3) · Nocturia (2) · Diarrhea (1) · Fecal Incontinence (1) · Urinary Bladder Diseases (1) · Urinary Incontinence, Stress (1) · Urologic Diseases (1)
Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Lower Urinary Tract Symptoms (6) · Male Urogenital Diseases (6) · Urogenital Diseases (6) · Urological Manifestations (6) · Urologic Diseases (5) · Urination Disorders (4) · Urinary Bladder Diseases (3) · Digestive System Diseases (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Rectal Diseases (1)
mirabegron (3) · Solifenacin Succinate (2) · Botulinum Toxins, Type A (1) · Injections (1) · Longitudinal Studies (1) · Music Therapy (1)
Astellas Pharma Europe B.V. (2) · Astellas Pharma Europe Ltd. (1) · Northwestern University (1) · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (1) · Umeå University (1) · University of California, San Francisco (1)
Sweden (4) · United States (4) · Czechia (3) · Denmark (3) · Slovakia (3) · Spain (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Bulgaria (2) · Canada (2) · Estonia (2) · Finland (2) · Germany (2) · Greece (2)
Alison Huang, MD (1) · Ina Asklund, MD, PhD (1) · Kimberly Kenton, M.D. (1)
PMID 29254376, PMID 29866467, PMID 33278293, PMID 33818395, PMID 35266189, PMID 37160401, PMID 38141064
R01AG047894 (1)